Shares of Acorda Therapeutics have moved sharply lower after Bloomberg reported that the company lost its bid for an injunction to block sales of a generic version of Ampyra. Acorda, whose main patent on Ampyra expires on July 30, is awaiting an appeals court decision on the validity of its patents for its prescription medicine indicated to help improve walking in adults with MS, noted Bloomberg. Acorda shares have come off their lows but remains down about 10% at $25.88 following the report on the ruling.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.